Leoni, S. et al. Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis. World J. Gastroenterol. 24, 3361–3373 (2018).
Karlas, T., Wiegand, J. & Berg, T. Gastrointestinal complications of obesity: Non-alcoholic fatty liver disease (NAFLD) and its sequelae. Best Pract. Res. Clin. Endocrinol. Metab. 27, 195–208 (2013).
Younossi, Z. M. et al. Global epidemiology of nonalcoholic fatty liver disease—Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64, 73–84 (2016).
EASL, EASD & EASO. European Association For The Study Of The Liver (EASL) – European Association For The Study Of Diabetes (EASD) – European Association For The Study Of Obesity (EASO): Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Diabetologia 59, 1121–1140 (2016).
Hagström, H. et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J. Hepatol. 67, 1265–1273 (2017).
Dulai, P. S. et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. Hepatology 65, 1557–1565 (2017).
Angulo, P. et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 149, 389–397 (2015).
Estes, C., Razavi, H., Loomba, R., Younossi, Z. & Sanyal, A. J. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology 67, 123–133 (2018).
Sidhu, P. S. et al. EFSUMB guidelines on interventional ultrasound (INVUS), Part II—diagnostic ultrasound-guided interventional procedures (Long Version) TT – EFSUMB Leitlinien interventioneller Ultraschall (INVUS), Teil II – Diagnostische Ultraschall-gestützte Interventi. Ultraschall. Med. 36, E15–E35 (2015).
Lorentzen, T. et al. EFSUMB guidelines on interventional ultrasound (INVUS), Part I. General aspects (long version). Ultraschall Med. 36, E1-14 (2015).
Bedossa, P. & Carrat, F. Liver biopsy: The best, not the gold standard. J. Hepatol. 50, 1–3 (2009).
Blond, E. et al. EASL–EASD–EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease in severely obese people: Do they lead to over-referral?. Diabetologia 60, 1218–1222 (2017).
European Association for Study of Liver & Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J. Hepatol. 63, 237–64 (2015).
Dietrich, C. F. et al. EFSUMB guidelines and recommendations on the clinical use of liver ultrasound elastography, update 2017 (long version). Ultraschall der Medizin 38, e16–e47 (2017).
Petta, S. et al. Serial combination of non-invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with NAFLD. Aliment. Pharmacol. Ther. 46, 617–627 (2017).
Eddowes, P. J. et al. Accuracy of fibroscan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology 156, 1717–1730 (2019).
Boursier, J. & Francque, S. Noninvasive tests of liver fibrosis and their combination in NAFLD: From selected patients to real-life populations. Hepatology 70, 1500–1502 (2019).
Roeb, E. et al. S2k Guideline non-alcoholic fatty liver disease. Z Gastroenterol. 53, 668–723 (2015).
Petroff, D., Blüher, M. & Wiegand, J. Knowledge and practice regarding the German and the EASL-EASD-EASO NAFLD-guidelines among members of the German obesity society. Dig. Liver Dis. 50, 731–733 (2018).
Rinella, M. E. et al. Practice patterns in NAFLD and NASH: Real life differs from published guidelines. Therap. Adv. Gastroenterol. 9, 4–12 (2016).
Byrne, C. D. & Targher, G. EASL–EASD–EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease: Is universal screening appropriate?. Diabetologia 59, 1141–1144 (2016).
Newsome, P. N. et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: A prospective derivation and global validation study. Lancet Gastroenterol. Hepatol. 5, 362–373 (2020).
Petersmann, A. et al. Definition, classification and diagnosis of diabetes mellitus. Exp. Clin. Endocrinol. Diabetes S01, S1–S7 (2019).
Rydén, L. et al. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur. Heart J. 34, 3035–3087 (2013).
European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) & European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol. 64, 1388–402 (2016).
European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) & European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease. Obes. Facts 9, 65–90 (2016).
Karlas, T. et al. Non-invasive assessment of hepatic steatosis in patients with NAFLD using controlled attenuation parameter and 1H-MR spectroscopy. PLoS ONE 9, e91987 (2014).
Sasso, M. et al. Controlled attenuation parameter (CAP): A novel VCTE guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: Preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med. Biol. 36, 1825–1835 (2010).
Karlas, T. et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J. Hepatol. 66, 1022–1030 (2017).
McPherson, S. et al. Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis. Am. J. Gastroenterol. 112, 740–751 (2017).
Sterling, R. K. et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 43, 1317–1325 (2006).
Karlsen, T. H., Lammert, F. & Thompson, R. J. Genetics of liver disease: From pathophysiology to clinical practice. J. Hepatol. 62, S6–S14 (2015).
Loomba, R. et al. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology 56, 943–951 (2012).
Harman, D. J. et al. Obesity and type 2 diabetes are important risk factors underlying previously undiagnosed cirrhosis in general practice: A cross-sectional study using transient elastography. Aliment. Pharmacol. Ther. 47, 504–515 (2018).
Karlas, T., Wiegand, J. & Petroff, D. Do NAFLD-patients require HCC screening?. Z. Gastroenterol. 57, 160–161 (2019).
Ratziu, V. et al. A survey of patterns of practice and perception of NAFLD in a large sample of practicing gastroenterologists in France. J. Hepatol. 57, 376–383 (2012).
Marjot, T. et al. Prevalence and severity of non-alcoholic fatty liver disease are underestimated in clinical practice: Impact of a dedicated screening approach at a large university teaching hospital. Diabet. Med. 35, 89–98 (2018).
Lai, L.-L. et al. Screening for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography. J. Gastroenterol. Hepatol. 34, 1396–1403 (2019).
Kwok, R. et al. Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: A prospective cohort study. Gut 65, 1359–1368 (2016).
Cherpitel, C. J. & Ye, Y. Validity of self-reports of drinking before injury by cause of injury and societal context among emergency department patients. Drug Alcohol Rev. 38, 523–529 (2019).
Serra-Burriel, M. et al. Transient elastography for screening of liver fibrosis: Cost-effectiveness analysis from six prospective cohorts in Europe and Asia. J. Hepatol. 71, 1141–1151 (2019).
Mahady, S. E. et al. Diagnostic accuracy of noninvasive fibrosis scores in a population of individuals with a low prevalence of fibrosis. Clin. Gastroenterol. Hepatol. 15, 1453-1460.e1 (2017).
Sberna, A. L. et al. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) clinical practice recommendations for the management of non-alcoholic fatty liver disease: Evaluation of their application in people with Type 2 diabetes. Diabet. Med. 35, 368–375 (2018).
Bril, F. et al. Performance of plasma biomarkers and diagnostic panels for nonalcoholic steatohepatitis and advanced fibrosis in patients with type 2 diabetes. Diabetes Care 43(2), 290–297 (2020).
Kleiner, D. E. et al. Association of histologic disease activity with progression of nonalcoholic fatty liver disease. JAMA Netw. open 10, e1912565 (2019).
Romeo, S. et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 40, 1461–1465 (2008).
Krawczyk, M., Portincasa, P. & Lammert, F. PNPLA3-associated steatohepatitis: toward a gene-based classification of fatty liver disease. Semin. Liver Dis. 33, 369–379 (2013).
Basyte-Bacevice, V. et al. TM6SF2 and MBOAT7 gene variants in liver fibrosis and cirrhosis. Int. J. Mol. Sci. 20, 2 (2019).
Ekstedt, M. et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 61, 1547–1554 (2015).
Thiagarajan, P. & Aithal, G. P. Drug development for nonalcoholic fatty liver disease: Landscape and challenges. J. Clin. Exp. Hepatol. 9, 515–521 (2019).
Mizuno, M. et al. Classification of patients with non-alcoholic fatty liver disease using rapid immunoassay of serum type IV collagen compared with liver histology and other fibrosis markers. Hepatol. Res. 47, 216–225 (2017).